{"filing":{"accession_number":"0001372514-26-000079","cik":"0001372514","ticker":"KPHMW","company_name":"KIORA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"kprx-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000079/kprx-20260908.htm"},"events":[{"id":31771,"run_id":29171,"accession_number":"0001372514-26-000079","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026. Lane brings 20+ years of ophthalmology experience and previously served as Chief Scientific Officer at Ora, Inc. The appointment includes compensatory terms of $350,000 base salary, $75,000 sign-on bonus, 35% performance bonus target, and 55,000 stock options.","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34752,"accession_number":"0001372514-26-000079","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026. While the Offer Letter includes compensatory terms (base salary of $350,000, sign-on bonus of $75,000, performance bonus target of 35%, and stock option grant of 55,000 shares), the principal disclosed action is the appointment of a named executive to a senior officer role. The compensation details are ancillary to the appointment itself. This is material to investors as it reflects leadership changes in a clinical-stage biotechnology company's development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:07:02.947934+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34753,"accession_number":"0001372514-26-000079","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs, a named executive officer role. The press release emphasizes his 20+ years of ophthalmology experience, prior role as Chief Scientific Officer at Ora, Inc., and his responsibilities for U.S. and global clinical development and registration studies for Kiora's pipeline, including KIO-301. This is a material executive appointment that would affect investor assessment of the company's clinical development capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:07:02.947934+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34752,"accession_number":"0001372514-26-000079","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026. While the Offer Letter includes compensatory terms (base salary of $350,000, sign-on bonus of $75,000, performance bonus target of 35%, and stock option grant of 55,000 shares), the principal disclosed action is the appointment of a named executive to a senior officer role. The compensation details are ancillary to the appointment itself. This is material to investors as it reflects leadership changes in a clinical-stage biotechnology company's development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:07:02.947934+00:00","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-09-08"},{"id":34753,"accession_number":"0001372514-26-000079","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs, a named executive officer role. The press release emphasizes his 20+ years of ophthalmology experience, prior role as Chief Scientific Officer at Ora, Inc., and his responsibilities for U.S. and global clinical development and registration studies for Kiora's pipeline, including KIO-301. This is a material executive appointment that would affect investor assessment of the company's clinical development capabilities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:07:02.947934+00:00","company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPHMW","filing_date":"2026-09-08"}]}